The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
Erythropoietic Protoporphyria Research and Education Fund
Harvard Medical School
Boston, MA 02115
The Erythropoietic Protoporphyria Research and Education Fund (EPPREF) is a non-profit organization dedicated to disseminating knowledge about erythropoietic protoporphyria (EPP) to affected individuals, physicians, and the general public; operating and maintaining a referral service for individuals with EPP; and assisting physicians in any way necessary to bring about optimal care for affected individuals. Erythropoietic protoporphyria is a rare, inherited, metabolic disorder characterized by a deficiency of the enzyme ferrochelatase (FECH). Due to abnormally low levels of FECH, excessive amounts of protoporphyrin accumulate in the plasma, red blood cells, and liver. Symptoms may include hypersensitivity of the skin to sunlight and some types of artificial light (photosensitivity); itchiness and redness of the skin and/or a burning sensation after exposure to light, particularly on the skin of the hands, arms, and face; and/or, in rare cases, complications related to liver and gallbladder function. Established in 1978, the EPPREF offers information to physicians, maintains a registry, and publishes articles concerning EPP within the peer-reviewed medical literature.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and that credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions are strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.